The EZR Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the EZR gene in the human Raji B lymphocyte cell line. This loss-of-function model eliminates ezrin protein expression, providing researchers with a robust tool to investigate the roles of ezrin in membrane-cytoskeletal interactions and downstream signaling without the confounding effects of monoclonal selection. The polyclonal nature retains genetic diversity inherent to the editing process, making it suitable for bulk population studies.
Raji cells are an Epstein-Barr virus (EBV)-positive Burkitt lymphoma-derived B lymphocyte line widely employed in immunology and oncology research. These cells exhibit characteristics of mature B lymphocytes, including antibody production and antigen presentation capabilities. Their well-characterized growth properties and susceptibility to CRISPR/Cas9 editing make them an ideal host for studying gene function in a B-cell malignancy context. The EBV-positive background also provides a unique platform to explore interactions between viral latency and host cell signaling.
Ezrin, encoded by the EZR gene, is a cytoplasmic peripheral membrane protein that links the plasma membrane to the actin cytoskeleton. It is a key member of the ERM (ezrin?Cradixin?Cmoesin) protein family and functions as a signal integrator. Ezrin is activated through phosphorylation at threonine 567 (T567) by kinases including RhoA/ROCK signaling, EGFR kinase, and protein kinase C (PKC), and its membrane association is regulated by PIP2. Once activated, ezrin interacts with transmembrane proteins such as CD44, ICAM-1, ICAM-2, and E-cadherin, and scaffolds adaptors like NHERF1/EBP50, thereby organizing cortical actin and modulating cell adhesion, shape, and migration. Downstream, ezrin-mediated signaling feeds into pathways such as PI3K/Akt, influencing cell survival and proliferation.
In Raji B lymphocytes, ezrin is implicated in B cell receptor (BCR) signal transduction and the control of cell adhesion and motility. Knockout of EZR in these cells disrupts the membrane?Ccytoskeletal linkage, likely impairing BCR clustering, immunological synapse formation, and antigen-triggered cytoskeletal reorganization. This model thus enables dissection of ezrin-dependent mechanisms underlying lymphoma cell homing, tissue invasion, and metastatic behavior. The polyclonal knockout population allows assessment of heterogeneous cellular responses, reflecting the variability seen in patient tumors.
The EZR Knockout Raji Polyclonal Cells are particularly suited for advanced cancer research and drug discovery applications. They can be employed in transwell migration and cell adhesion assays to evaluate lymphoma cell motility, in western blotting and phospho-specific T567 analysis to monitor ezrin signaling status, and in immunofluorescence microscopy to visualize actin cytoskeleton rearrangements and protein localization. In addition, these cells facilitate BCR signaling studies by flow cytometry and support target validation efforts for anti-metastatic therapies. For further details, please contact Ascent Research.
